Inpatient management and post-discharge outcomes of hyperkalemia

References

• Coutrot M, Depret F, Legrand M. Tailoring treatment of hyperkalemia. Nephrol Dial Transplant. 2019;34(Supplement_3):iii62–iii8.
   PubMedGoogle Scholar
• Nyirenda MJ, Tang JI, Padfield PL, et al. Hyperkalaemia. BMJ. 2009;339:b4114. DOI:https://doi.org/10.1136/bmj.b4114
   Google Scholar
• Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a danish population-based cohort study. J Am Heart Assoc. 2018;7(11). DOI:https://doi.org/10.1161/JAHA.118.008912.
   Google Scholar
• Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–548.
   PubMed Web of Science ®Google Scholar
• Desai AS, Swedberg K, McMurray JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J Am Coll Cardiol. 2007;50(20):1959–1966.
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, et al. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971–978.
   PubMed Web of Science ®Google Scholar
• Khedr E, Abdelwhab S, El-Sharkawy M, et al. Prevalence of hyperkalemia among hemodialysis patients in Egypt. Ren Fail. 2009;31(10):891–898.
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, et al. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385–393.
   PubMed Web of Science ®Google Scholar
• Dunn JD, Benton WW, Orozco-Torrentera E, et al. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21(15Suppl):s307–15.
   PubMedGoogle Scholar
• Mushiyakh Y, Dangaria H, Qavi S, et al. Treatment and pathogenesis of acute hyperkalemia. J Community Hosp Intern Med Perspect. 2012;1(4). DOI:https://doi.org/10.3402/jchimp.v1i4.7372
   Google Scholar
• Rossignol P, Legrand M, Kosiborod M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016;113:585–591.
   PubMed Web of Science ®Google Scholar
• Depret F, Peacock WF, Liu KD, et al. Management of hyperkalemia in the acutely ill patient. Ann Intensive Care. 2019;9(1):32.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP. Management of hyperkalemia: an update for the internist. Am J Med. 2015;128(12):1281–1287.
   PubMed Web of Science ®Google Scholar
• Peacock WF, Rafique Z, Clark CL, et al. Real world evidence for treatment of hyperkalemia in the emergency department (REVEAL-ED): a multicenter, prospective, observational study. J Emerg Med. 2018;55(6):741–750.
   PubMed Web of Science ®Google Scholar
• Acker CG, Johnson JP, Palevsky PM, et al. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158(8):917–924.
   PubMedGoogle Scholar
• Paice B, Gray JM, McBride D, et al. Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed). 1983;286(6372):1189–1192.
   PubMedGoogle Scholar
• Shemer J, Modan M, Ezra D, et al. Incidence of hyperkalemia in hospitalized patients. Isr J Med Sci. 1983;19(7):659–661.
   PubMedGoogle Scholar
• An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16(6):R225.
   PubMed Web of Science ®Google Scholar
• Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med. 2000;160(11):1605–1611.
   PubMedGoogle Scholar
• Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014;10(2):251–257.
   PubMed Web of Science ®Google Scholar
• Mu F, Betts KA, Woolley JM, et al. Prevalence and economic burden of hyperkalemia in the United States medicare population. Curr Med Res Opin. 2020;36(8):1333–1341.
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, et al. (2020) Postdischarge Healthcare Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations. Kidney International Reports.
   Google Scholar
• National Kidney Foundation (2021). Facts about high potassium in patients with kidney disease. https://www.kidney.org/atoz/content/hyperkalemia/facts. Accessed 2021 Mar 19.
   Google Scholar
• Kraft MD, Btaiche IF, Sacks GS, et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm. 2005;62(16):1663–1682.
   PubMed Web of Science ®Google Scholar
• Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–1162.
   PubMed Web of Science ®Google Scholar
• Knoll GA, Sahgal A, Nair RC, et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112(2):110–114.
   PubMed Web of Science ®Google Scholar
• Hagan AE, Farrington CA, Wall GC, et al. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study. Clin Nephrol. 2016;85(1):38–43.
   PubMed Web of Science ®Google Scholar
• Kessler C, Ng J, Valdez K, et al. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011;6(3):136–140.
   PubMed Web of Science ®Google Scholar
• Batterink J, Lin J, Au-Yeung SH, et al. Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia. Can J Hosp Pharm. 2015;68(4):296–303.
   PubMedGoogle Scholar
• Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci. 2014;347(2):93–100.
   PubMed Web of Science ®Google Scholar
• Montford JR, Linas S. How dangerous is hyperkalemia? J Am Soc Nephrol. 2017;28(11):3155–3165.
   PubMed Web of Science ®Google Scholar
• Chaitman M, Dixit D, Bridgeman MB. Potassium-binding agents for the clinical management of hyperkalemia. P T. 2016;41(1):43–50.
   PubMedGoogle Scholar
• Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264e9–24.
   Web of Science ®Google Scholar
• Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med. 2019;179(8):1025–1033.
   PubMed Web of Science ®Google Scholar
• Grodzinsky A, Goyal A, Gosch K, et al. Prevalence and prognosis of hyperkalemia in patients with acute myocardial infarction. Am J Med. 2016;129(8):858–865.
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Spoletini I, Agewall S. Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate. Eur Heart J Suppl. 2019;21(Supplement_A):A28–A33.
   PubMed Web of Science ®Google Scholar
• Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium Zirconium cyclosilicate among individuals with hyperkalemia. Clin J Am Soc Nephrol. 2019;14(6):798.
   PubMed Web of Science ®Google Scholar
• Colbert GB, Patel D, Lerma EV. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020;13(6):563–570.
   PubMedGoogle Scholar
• Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510–1513.
   PubMed Web of Science ®Google Scholar
• McMahon GM, Mendu ML, Gibbons FK, et al. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. 2012;38(11):1834–1842.
   PubMed Web of Science ®Google Scholar